Ian Postlethwaite

Ian Postlethwaite brings over 14 years of biopharma experience and a proven track record of driving revenue growth and funding development programs. He has broad experience in both private and public companies; from start-ups to multi-nationals.

He was previously an Executive Director on the board of Allergy Therapeutics plc. He joined Allergy in April 2002 as Finance Director whilst it was private company, initially performing a financial turnaround and then listing it two years later in 2004 on the AIM of the London Stock Exchange. Revenue increased from £12 to c.£49m over his tenure and he raised £107m through equity issues and €40m through debt finance to fund over 15 clinical studies.

Prior to this he worked for Ellerman Investments (1997-2002), a UK private equity house, undertaking the roles of Chief Executive Officer with AFS, which was one of the largest independent finance houses in the UK, raising over £400m in debt finance, and Finance Director with a number of successful start-up technology companies. Previously he held senior finance positions with Ericsson and Philips Electronics.

He is also a non-executive director and Deputy Chairman of Shoreham Port. He is a Fellow of the Chartered Association of Certified Accountants and has a BSc (Hons) in Geological Sciences from Aston University.

Ian Postlethwaite

Non-executive Director
Ian Postlethwaite
Dr David Ribeiro

Dr David Ribeiro

CEO
Dr Ribeiro has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and Pfizer.
Read More
François Martelet

François Martelet

Chairman
François Martelet brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad
Read More
Brian Walker

Brian Walker

CSO
Professor Walker has over 30 years experience in the design & synthesis of “Protease-Tags” for the identification and validation of protease targets of biomedical and
Read More
David Moore

David Moore

Head of Spin Outs & Investments, QUBIS Ltd.
David is Investment Manager with QUBIS Ltd, the early stage investment fund responsible for the commercialisation of technology from The Queen’s University of Belfast.
Read More
Lorraine Martin

Lorraine Martin

Non-executive Director
Dr Lorraine Martin is a co-founder of ProAxsis Ltd. and a Senior Lecturer in Molecular Pharmaceutics within the School of Pharmacy, Queen’s University Belfast.
Read More
Ernest Schneider

Ernest Schneider

Non-executive Director
Ernest Schneider is a solicitor, patent & trade mark attorney and accredited mediator. He is the Commercial-Legal Director and Company Secretary of NetScientific plc and
Read More